About
REINVENTING HOW PRESCRIBERS AND PATIENTS MANAGE PAIN
Probudur is being developed using our next-generation liposomal encapsulation to satisfy an unmet post-surgical pain need. In our preclinical studies, Probudur significantly increased the residence time of bupivacaine at the surgical site thereby allowing for a much longer duration of analgesia. It is hypothesized that this prolonged period of effective post-operative pain relief for up to 4 days, will allow patients to move past the most acute period of post-operative pain and will reduce the need to prescribe opioids.
Virpax is committed to developing non-addictive product candidates that manage severe pain. By combining compatible drug compounds with our cutting‑edge drug-delivery platforms, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary drug-delivery platforms will reinvent how patients and prescribers manage pain worldwide.
REINVENTING HOW WE DIRECTLY TARGET THE BRAIN TO MANAGE CNS DISORDERS
Our patented Molecular Envelope Technology (MET) platform is being used to grow our Central Nervous System (CNS) disorder pipeline. The current CNS product indications include Post Traumatic Stress Disorder (PES200), and Rare Pediatric Epilepsy (NobrXiol).
MET will significantly improve our drug delivery process characteristics by directly targeting the brain to manage CNS disorder symptoms.
Virpax is collaborating with the National Advisory Neurological Disorders and Stroke Council (NINDS) and Epilepsy Therapy Screening Program (ETSP) to begin preclinical development of NobrXiol for the treatment of pediatric epilepsy. The mission of ETSP is to identify novel agents that may address unmet medical needs in epilepsy.
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic.
FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management lasting up to 30 days, in response to some form of tissue injury, such as trauma or surgery.
February 2022
We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders, including rare and orphan diseases.
We are seeking FDA approval in three multi-billion dollar markets as we strive to promptly advance our robust pipeline. If approved, our product candidates will fundamentally change what prescribers recommend to manage their patients’ severe pain, Epilepsy, and other CNS disorders in the future.
